Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for In8bio Inc. (INAB:NASDAQ), powered by AI.
In8bio Inc. is currently trading at $1.38. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for In8bio Inc. on Alpha Lenz.
View In8bio Inc.'s valuation metrics on Alpha Lenz.
“In8bio Inc.'s ROE is -92.5%. Explore profitability and growth together.”
Ask for details →In8bio Inc. is a biotechnology company focused on developing innovative therapies in the field of immuno-oncology. The primary mission of In8bio Inc. is to harness the unique properties of gamma-delta T cells, a distinct type of immune cell, to create therapies aimed at combating cancer. With a strong foundation in cellular therapy, the company is pioneering novel approaches that leverage these cells' innate ability to target and destroy cancerous cells while sparing normal ones. This focus not only underscores the potential for improved patient outcomes but also highlights a growing interest in next-generation cancer treatments. Operating within the broader biotechnology sector, In8bio Inc. contributes to the progressive shift towards personalized medicine and precision health. Through its research and development efforts, In8bio Inc. is strategically positioned to influence the therapeutic landscape by providing alternative treatment options that address unmet medical needs in oncology. The company's commitment to converting scientific discovery into impactful treatments underscores its role in advancing biotechnological innovations across global medical communities.
“In8bio Inc.'s ROE is -92.5%. Explore profitability and growth together.”
Ask for details →In8bio Inc. (ticker: INAB) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 18 employees.
The current price is $1.38 with a P/E ratio of -x and P/B of -x.
ROE is -92.49%.